ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1866

Vasculitis in Patients with Sarcoidosis: A Single-Institution Case Series of 17 Patients

Bradly Kimbrough1, Kenneth Warrington2, Hannah Langenfeld3, Cynthia Crowson4, Eva Carmona3, Andrew Virata3 and Matthew Koster3, 1Mayo Clinic Rochester, Rochester, MN, 2Mayo Clinic, Rochester, Minnesota, 3Mayo Clinic, Rochester, MN, 4Mayo Clinic, Eyota, MN

Meeting: ACR Convergence 2021

Keywords: sarcoidosis, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Vasculitis in patients with sarcoidosis is rare and can affect blood vessels of any size. Limited information describing this association is available. The purpose of this study is to describe a large, single-institution case-series of patients with sarcoidosis and vasculitis.

Methods: A single-institution retrospective study was performed reviewing all patients with a diagnosis code for sarcoidosis and vasculitis between January 1, 1998 and December 31, 2019. Medical records were individually reviewed, and data regarding diagnosis, treatment, and outcomes were abstracted. Sarcoidosis was diagnosed based on histologic, radiographic, and clinical data with exclusion of alternative diagnoses. Diagnosis for small vessel vasculitis (SVV) required biopsy confirmation. Patients with large or medium-vessel vasculitis (L/MVV) required biopsy and/or arterial imaging. Comparison between patients presenting with L/MVV versus patients with only SVV was performed.

Results: Seventeen patients were identified during the study period. Nine patients (56% female) had L/MVV and 8 (50% female) had SVV. Mean±SD age at sarcoidosis diagnosis was 53.2±17.8 and 51.9±11.4 years and mean±SD age at vasculitis diagnosis was 57.4±19.6 and 59.0±13.4 years in L/MVV and SVV groups, respectively. Number of organ systems involved by sarcoidosis was similar [median (IQR) 3 (1,4) L/MVV vs. 2.5 (1.75, 3.25) SVV]. Sarcoid organ involvement and vasculitis vessel distributions are noted in Table 1. Mean length of follow-up was 11.5±12.8 years in L/MVV and 13.1±14.3 years in SVV. All patients were treated with glucocorticoids for vasculitis. More patients with L/MVV were treated with at least one DMARD/biologic (8/9, 89%) compared to SVV (3/8, 38%, p=0.05). Complete response to therapy for vasculitis was observed in 8/9 L/MVV and 7/8 in SVV. Four patients in SVV group were able to stop all immunosuppression but only one patient with L/MVV was off all therapy at last follow-up.

Conclusion: Vasculitis in patients with sarcoidosis is uncommon. Variability exists in the vessels involved and the treatments utilized. Overall this series observed favorable outcomes with a high percentage achieving complete response, regardless of vessel size affected.

Table 1: Characteristics of vasculitis in patients with sarcoidosis


Disclosures: B. Kimbrough, None; K. Warrington, Eli Lilly, 5, Kiniksa, 5; H. Langenfeld, None; C. Crowson, None; E. Carmona, None; A. Virata, None; M. Koster, None.

To cite this abstract in AMA style:

Kimbrough B, Warrington K, Langenfeld H, Crowson C, Carmona E, Virata A, Koster M. Vasculitis in Patients with Sarcoidosis: A Single-Institution Case Series of 17 Patients [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/vasculitis-in-patients-with-sarcoidosis-a-single-institution-case-series-of-17-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/vasculitis-in-patients-with-sarcoidosis-a-single-institution-case-series-of-17-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology